AVTX Insider Trading

Insider Ownership Percentage: 0.25%
Insider Buying (Last 12 Months): $6,250.00
Insider Selling (Last 12 Months): $0.00

Avalo Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Avalo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Avalo Therapeutics Share Price & Price History

Current Price: $6.85
Price Change: Price Decrease of -1.16 (-14.48%)
As of 04/1/2025 05:00 PM ET

This chart shows the closing price history over time for AVTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$8.01Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for Avalo Therapeutics (NASDAQ:AVTX)

87.06% of Avalo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AVTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$6.68Mbought$685ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200M$0$200MTotal InflowsTotal Outflows
Avalo Therapeutics logo
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Read More on Avalo Therapeutics

Today's Range

Now: $6.85
Low: $6.81
High: $8.37

50 Day Range

MA: $7.65
Low: $6.59
High: $8.73

52 Week Range

Now: $6.85
Low: $5.99
High: $22.47

Volume

28,146 shs

Average Volume

72,146 shs

Market Capitalization

$73.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Who are the company insiders with the largest holdings of Avalo Therapeutics?

Avalo Therapeutics' top insider shareholders include:
  1. Armistice Capital, Llc (Major Shareholder)
  2. Caissa Capital Management Ltd (Major Shareholder)
  3. June Sherie Almenoff (Director)
  4. Garry Arthur Neil (CEO)
  5. Christopher Ryan Sullivan (CFO)
Learn More about top insider investors at Avalo Therapeutics.